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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
To identify genes and signaling pathways that
initiate Neurofibromatosis type 1 (NF1) neurofi-
bromas, we used unbiased insertional mutagenesis
screening, mouse models, and molecular ana-
lyses. We mapped an Nf1-Stat3-Arid1b/b-catenin
pathway that becomes active in the context of
Nf1 loss. Genetic deletion of Stat3 in Schwann
cell progenitors (SCPs) and Schwann cells (SCs)
prevents neurofibroma formation, decreasing SCP
self-renewal and b-catenin activity. b-catenin
expression rescues effects of Stat3 loss in SCPs.
Importantly, P-STAT3 and b-catenin expression
correlate in human neurofibromas. Mechanistically,
P-Stat3 represses Gsk3b and the SWI/SNF gene
Arid1b to increase b-catenin. Knockdown of
Arid1b or Gsk3b in Stat3fl/fl;Nf1fl/fl;DhhCre SCPs
rescues neurofibroma formation after in vivo trans-
plantation. Stat3 represses Arid1b through histone
modification in a Brg1-dependent manner, indi-
cating that epigenetic modification plays a role in
early tumorigenesis. Our data map a neural tumor-
igenesis pathway and support testing JAK/STATCeand Wnt/b-catenin pathway inhibitors in neurofi-
broma therapeutic trials.INTRODUCTION
Neurofibromas are benign peripheral nerve tumors that
cause significant morbidity by disfigurement and tissue
compression, and mortality if they compress vital organs
(Boyd et al., 2009). Neurofibromas are a major feature of
Neurofibromatosis type 1 (NF1), a common autosomal domi-
nant disorder affecting about 1 in 3,500 individuals. Surgery
remains the mainstay of neurofibroma therapy but is rarely
curative, so new treatments are urgently needed.
Peripheral nerve Schwann cells (SCs) are the primary
pathogenic cell in neurofibromas, as biallelic mutation or
loss of NF1 occurs uniquely in neurofibroma SCs (Serra
et al., 1997). Neurofibromas may develop from SCs or
Schwann cell progenitors (SCPs), because inactivation of
Nf1 at the SCP stage or in adult mice results in neurofibroma
formation (Chen et al., 2014; Wu et al., 2008; Zhu et al., 2002).
NF1 encodes the RasGAP protein neurofibromin, and
Ras signaling is elevated in neurofibroma SCs (Cichowski
and Jacks, 2001). Other genes and signaling pathways
that drive neurofibroma initiation and growth are largely
unknown.ll Reports 14, 1979–1990, March 1, 2016 ª2016 The Authors 1979
STAT3 is a latent transcription factor implicated in cancer,
which regulates cell-cycle progression and apoptosis. STAT3
phosphorylation at Y705 is essential for STAT3 dimerization,
required for STAT3 binding to DNA promoter regions and tran-
scriptional activation (Battle and Frank, 2002). Fewer benign le-
sions formed when Stat3 was absent in prostate and skin tumors
in vivo, implicating it in tumor initiation (Kim et al., 2009; Kroon
et al., 2013). Stat3 also regulates self-renewal and growth of gli-
oma stem cells (Sherry et al., 2009). Recent studies onmalignant
peripheral nerve sheath tumors (MPNSTs), aggressive nerve sar-
comas, implicate Stat3 in their growth (Banerjee et al., 2010; Wu
et al., 2014). The role of Stat3 in the benign nerve tumors (neuro-
fibromas) has not been studied.
Stat3 activated b-catenin through GSK3b in hepatocytes (Moh
et al., 2008). b-catenin is a developmental signaling pathway re-
activated in many cancers. How b-catenin becomes elevated
and if b-catenin plays a role in neurofibroma is unknown,
although neurofibroma b-catenin expression was reported (Lus-
can et al., 2014; Mo et al., 2013; Watson et al., 2013). In vivo acti-
vation of b-catenin in developing SCs delays SC differentiation
and results in sustained proliferation (Grigoryan et al., 2013),
supporting possible roles for b-catenin in nerve tumorigenesis.
Multi-subunit SWI/SNF chromatin remodeling complexes
modulate transcription factor access to target genes, resulting
in activation or repression of transcription (Tolstorukov et al.,
2013). Recent studies demonstratemutation or loss of chromatin
remodeling genes in progression to MPNSTs (De Raedt et al.,
2014; Lee et al., 2014), but are unstudied in neurofibromas.
Mutational inactivation of SWI/SNF complex genes, including
BRG1/SMARCA4, encoding a SWI/SNF ATPase, and SWI/SNF
subunit genes ARID1A and ARID1B, are increasingly implicated
in development and cancer (Helming et al., 2014; Sausen et al.,
2013). When an ARID1B-containing SWI/SNF complex is pre-
sent, interaction of STAT3 with DNA activates c-Myc transcrip-
tion in pre-osteoblast MC3T3-E1 cells (Nagl et al., 2007). Also,
BRG1 interacts with b-catenin to promote target gene activation
in colon cancer cells (Barker et al., 2001). In patients with intellec-
tual disability, ARID1B represses BRG1-dependent Wnt/b-cate-
nin signaling (Vasileiou et al., 2015).
We report results of an unbiased in vivo Sleeping Beauty inser-
tional mutagenesis transposon screen. We demonstrate a crit-
ical role of Stat3 in driving neurofibromas. Stat3 transcriptionally
represses Gsk3b and the SWI/SNF complex subunit Arid1b,
thereby activating b-catenin in SCPs and resulting in neurofi-
broma initiation and maintenance.
RESULTS
A Transposon System and Pathway Analysis Implicate
theWnt and Stat3 Pathways in Neurofibroma Formation
To identify mechanisms underlying neurofibroma growth and/or
tumor progression, we used insertional mutagenesis. We gener-
ated quadruple transgenic animals (Nf1fl/fl;DhhCre;Rosa26-lsl-
SB11;T2/Onc) (Figure S1A). Survival and onset of tumorigenesis
did not differ from control animals (data not shown), and neuro-
fibroma size was similar (p = 0.1996) (Figure S1B, top). However,
the number of neurofibromas isolated from experimental animals
was higher (5.4 versus 2.8; p = 0.1017) (Figure S1B, bottom). The1980 Cell Reports 14, 1979–1990, March 1, 2016 ª2016 The Authorstrend toward significance in this small sample set suggests
that transposition-related genes might play a role in increasing
neurofibroma numbers and/or growth.
To identify potential genes responsible for neurofibroma
tumorigenesis, we used high-throughput pyrosequencing of
neurofibromas isolated from experimental quadruple transgenic
animals. We identified 31 common transposon insertion sites
(CISs). We removed CISs identified in control insertion-site
mapping experiments in 3-week-old transgenic mouse tail
DNA carrying both the T2/Onc and Rosa26-SB11 transgenes,
and CISs identified in tumors from single mice. The remaining
22 CISs identified for neurofibroma tumorigenesis are shown in
Figure 1A.
We used the Genemania prediction server (http://www.
genemania.org) to predict pathways, interactions, and func-
tions of the 22 CIS genes, and we identified networks including
CIS genes. The most significantly deregulated pathways were
Wnt signaling (false discovery rate [FDR] = 0.021) including
CIS genes Tnks and Gsk3b, and major neighboring genes
Strn, Axin1, and Dvl1, and Stat3-associated cellular carbohy-
drate metabolic process (FDR = 0.023) including the CIS genes
Gsk3b and Arid1b and major neighboring genes Stat3 and
Ptpn2 (Figure 1B). Interestingly, Gsk3b connected these two
pathways in this in silico analysis. No tumor tissue from these
mice was available for confirmatory analysis. The other
signaling pathways identified by Genemania are shown in
Figure S1C.
STAT3/b-catenin Signaling Is Activated in Mouse and
Human Neurofibromas
We focused on STAT3, a known oncogene and therapeutic
target unstudied in neurofibromas. Antibodies recognizing
P-Stat3-Y705 detected positive cells in all genetically engi-
neered mouse (GEM) neurofibromas (n = 19) (Figure 2A), but
not wild-type (WT) mouse sciatic nerves (Figure 2A, inset). In
contrast, P-Stat3-Ser727 was detectable in one out of four
mice and one out of five human neurofibromas (data not shown).
Given the link between the Stat and Wnt pathways identified by
transposon mutagenesis, we tested if b-catenin is co-activated
with P-Stat3 in neurofibroma SCs. DhhCre activates EGFP
expression in the context of DhhCreNf1fl/fl mice in 40%–50%
of SCs, in a reporter mouse in which the CMV-b actin promoter
and loxP flanked CAT gene are upstream of the Egfp cassette
(Nakamura et al., 2006). We stained frozen sections of
Nf1fl/fl;DhhCre;EGFP mouse neurofibromas with anti-P-Stat3
and anti-b-catenin. Of EGFP-expressing SCs, 21% were
P-Stat3+ only, 62% expressed only b-catenin+, and, importantly,
6.7% of EGFP+ SCs were P-Stat3+ and b-catenin+ (Figure 2B).
Thus, P-Stat3 and b-catenin can be co-activated in SCs in
neurofibromas. We also detected Iba1+ macrophages that are
P-Stat3+;EGFP (data not shown). Western blots confirmed
robust P-Stat3-Y705 in mouse neurofibroma lysates versus WT
peripheral nerve (Figure 2C).
We immunolabeled human plexiform neurofibroma sections to
test if P-STAT3 and b-catenin expression correlate. Most (29/30)
contained P-Y705-STAT3+ and b-catenin+ cells (Figures 2D–2F).
Some neurofibroma cells showed cytoplasmic staining (43%),
others showed nuclear staining (23%), and 34.2% showed
Figure 1. Genes Identified by Sleeping
Beauty Transposon System Predict Stat3
and Wnt Pathway Activation in Neurofi-
broma
(A) Common insertion sites (CISs) identified from
neurofibromas. The positions were based on the
Ensembl NCBI m37 April 2007 mouse assembly.
(B) Genemania pathway analysis using 22 CIS
(black) and 20 genes (gray) connected to CIS
by genetic, physical, or Stat3 pathway analysis
identifies two significantly deregulated networks.
Wnt signaling related gene names are shown in
red, and cellular carbohydrate metabolic process
related genes are in pink. GSK3b (turquoise)
connects these pathways to those in Figure S2.
Circle size correlates to network association
probabilities.both. There was a significant correlation between P-STAT3 and
total b-catenin (Figures 2E and 2F). Thus, the STAT3 and b-cat-
enin pathways are activated in human neurofibromas and are
highly correlated.
Targeted Genetic Deletion of Stat3 in SCs and SCPs
Decreases Neurofibroma Numbers and Delays
Neurofibroma Formation In Vivo
We then tested whether activation of Stat3 in SCs and SCPs is
necessary for neurofibroma initiation and/or maintenance. Loss
of Stat3 in Stat3 fl/fl;DhhCre mice had no influence on peripheral
(saphenous) nerve structure, as shown by electron microscopy;
Remak bundles and myelinated axons showed normal differen-
tiatedmorphology (Figures S2A and S2B). We bred Stat3fl/fl mice
onto Nf1fl/fl;DhhCre mice; this required generating recombi-
nants, as both Nf1 and Stat3 reside on mouse chromosome
11. Kaplan-Meier survival analysis revealed a significant di-
fference in mouse survival between Stat3fl/fl;Nf1fl/fl;DhhCre
mice and Stat3fl/+;Nf1fl/fl;DhhCre mice (p < 0.001) or be-
tween Stat3fl/fl;Nf1fl/fl;DhhCre mice and Nf1fl/fl;DhhCre miceCell Reports 14, 1979–199(p < 0.001). Loss of one Stat3 allele
does not influence survival (Stat3fl/+;
Nf1fl/fl;DhhCre mice versus Nf1fl/fl;
DhhCre mice; p = 0.66) (Figure 3A).
Nf1fl/fl;DhhCre nerves continually and
significantly increased in size, corre-
sponding to neurofibroma initiation and
neurofibroma growth reported in this
model (Wuet al., 2008). Representative tu-
mors at 9 months are shown in a
Nf1fl/fl;DhhCre versus a Stat3fl/fl;Nf1fl/fl;
DhhCremouse (Figure 3B). We quantified
total neurofibroma burden by volumetric
measurement of MRI scans, followed by
mixed effects analysis of tumor volume.
Strikingly, doublemutant nerves (average,
20 mm3) were similar to WT nerves
(8–19mm3) (Figure 3C). The differencebe-
tween controls (Nf1fl/fl;DhhCre or Stat3fl/+;
Nf1fl/fl;DhhCre; n = 9) and Stat3fl/fl;Nf1fl/fl;DhhCre mice (n = 15) was significant (p < 0.001 at 4, 7, and
9 months; Figures S2C and S2D).
In the Nf1fl/fl;DhhCre model, each mouse develops 4–20
neurofibromas. If Stat3 contributes to neurofibroma initiation,
then tumor number should be reduced in Stat3 mutants.
Indeed, Stat3fl/fl;Nf1fl/fl;DhhCre mice had significant fewer
tumors per mouse versus Stat3fl/+;Nf1fl/fl;DhhCre littermates
upon spinal cord dissection in 5-month-old mice (Figure 3D).
Confirming volumetric MRI scan results, the neurofibroma
diameter measured at spinal roots upon dissection was
significantly smaller in Stat3fl/fl;Nf1fl/fl;DhhCre versus Stat3fll+;
Nf1fl/fl;DhhCre mice (Figure 3E). Rare small neurofibromas
showed hyperplasia or GEM grade 1 neurofibroma histology
(Figure S3). Ki67+ proliferating cells in neurofibroma tissue
sections significantly decreased in Stat3fl/fl;Nf1fl/fl;DhhCre
neurofibromas (Figure 3F); numbers of dying cells were
unchanged (CC3+) (Figure 3G). Importantly, Stat3 protein
was absent in flow-cytometry-sorted EGFP+ SCPs and SCs
from Stat3fl/fl;Nf1fl/fl;DhhCre;EGFP+ mice (Figure 3H); we did,
however, detect increased levels of Stat1 and Stat5 (data0, March 1, 2016 ª2016 The Authors 1981
Figure 2. P-STAT3 and b-catenin Expression Correlate in Mouse and Human Neurofibromas
(A) P-Stat3 immunostaining inmouse neurofibromas andWT sciatic nerves (inset), visualizedwith DAB (brown). Nuclei are counterstainedwith hematoxylin (blue).
(B) Representative immunofluorescent images show EGFP+ SCs (white arrows); some are also P-Stat3+ (purple) and b-catenin+ (red). Neurofibromas from three
mice (four sections per tumor) were stained. 350–500 EGFP+ cells were counted per section. DAPI (blue) staining highlights nuclei. Mean ± SEM is shown.
(C) Western blot of P-Stat3-Y705 (P-Stat3) and total Stat3 (Stat3) in mouse neurofibroma (tumor) and WT sciatic nerve (WT nerve); blot is representative of
neurofibromas (n = 5) and WT nerves (n = 3).
(D) Representative pictures of immunostaining of P-STAT3(Y705) (left) and b-catenin (right) in human plexiform neurofibroma. On the right, the black arrow in-
dicates nuclear b-catenin, the white arrows indicate cytoplasmic b-catenin, and the black arrowhead indicates both. Scale bar, 10 mm.
(E) Distribution of% P-STAT3 positive neurofibroma cells versus% nuclear b-catenin positive only (blue) or cytoplasmic and/or nuclear b-catenin positive (red) in
30 human plexiform neurofibromas. Spearman correlation coefficient analysis between P-STAT3(Y705) and b-catenin distribution (P-STAT3 versus total beta
catenin shown in red, r = 0.7219, p < 0.0001; P-STAT3 versus nuclear beta catenin shown in blue, r = 6374, p = 0.0002, two-tailed).
(F) Quantification of intensity of P-STAT3(Y705) and b-catenin immune-positive cells in NF1 human plexiform neurofibromas and Spearman correlation coefficient
analysis between P-STAT3(Y705) and b-catenin intensity (r = 0.4373; p = 0.0157, two-tailed).not shown). Therefore, glial cell Stat3 regulates tumor cell
proliferation in neurofibromas, and activation of Stat3 in SCs
and/or SCPs is important for neurofibroma initiation and
growth.
Stat3 Contributes to Neurofibroma Initiation
Our in vivo analyses could not distinguish function(s) of P-Stat3
in neurofibroma SCs versus SCPs, because the genetic loss of
function targets both. To confirm that Stat3 is relevant to neuro-1982 Cell Reports 14, 1979–1990, March 1, 2016 ª2016 The Authorsfibroma SCP-like cells, we used sphere culture, enabling detec-
tion of growth and self-renewal of nervous system stem and/or
progenitors. We isolated cells directly from human plexiform
neurofibromas and cultured them as floating spheres at clonal
density. We blocked STAT3 signaling with FLLL32, a JAK2/
STAT3 inhibitor (Lin et al., 2010). FLLL32 inhibited human
neurofibroma sphere formation (IC50, 0.3 mM) (Figures 4A and
4B). Western blot confirmed decreased STAT3-Y705 phos-
phorylation and slightly reduced total STAT3 (Figure 4C).
Figure 3. Targeted Genetic Deletion of Stat3 in SCs and SCPs Delays Neurofibroma Formation In Vivo
(A) Kaplan-Meier survival curve. Purple: Stat3 fl/fl;Nf1fll+;DhhCre. Red: Stat3fl/fl;Nf1fl/fl;DhhCre. Blue: Stat3 fl/+;Nf1fl/fl;DhhCre. Green: Nf1fl/fl;DhhCre.
(B) Representative gross dissections of thoracic paraspinal neurofibromas and nerve roots in 9-month-old Nf1fl/fl;DhhCre (left) and Stat3fl/fl;Nf1fl/fl;DhhCre (right)
mice. The ruler shows 1-mm markings.
(C) Neurofibroma volumes at 4, 7, and 9months of age, measured inMRI images.Nf1fl/fl;DhhCremice (n = 12, black bars) andStat3fl/fl;Nf1fl/fl;DhhCremice (n = 15,
white bars) at 4, 7, and 9 months of age are shown.
(D) Average tumor number per mouse at 5 months in the Stat3fl/fl;Nf1fl/fl;DhhCre (white bar, n = 6) and littermates Stat3fll+;Nf1fl/fl;DhhCremice (black bar, n = 6).
(E) Tumor diameter in the Stat3fl/fl;Nf1fl/fl;DhhCre (circle, n = 6 mice with 57 tumors) and littermates Stat3fll+;Nf1fl/fl;DhhCre mice (triangle, n = 6 mice with 21
tumors).
(F) Cell proliferation shown as percent Ki67+ cells in Nf1fl/fl;DhhCre mice (n = 4, black bar) and Stat3fl/fl;Nf1fl/fl;DhhCre mice (n = 3, white bar).
(G) Cell death shown as percent cleaved caspase 3+ cells in Nf1fl/fl;DhhCre mice (n = 4, black bar) and Stat3fl/fl;Nf1fl/fl;DhhCre mice (n = 3, white bar).
(H) Western blot on FACS-sorted EGFP+, EGFP cells dissociated from adult Stat3fl/fl;DhhCre;EGFPfl/fl mouse sciatic nerves.
Statistics: ordinary one-way ANOVA (C) and unpaired Student’s t test (D–G). * = p < 0.05, ** = p < 0.01, ** = p < 0.001, n.s. = not significant.Importantly, FLLL32 inhibited the formation of Nf1/ SCP
spheres (IC50, 0.5–1 mM), yet affected WT SCPs only at 103
higher concentration (Figure 4D). We also dissociated dorsal
root ganglia (DRG) and/or early neurofibromas from 6-week-
old mice. Stat3fl/fl;Nf1fl/fl;DhhCre cells formed significantly
fewer primary and secondary spheres than Nf1fl/fl;DhhCre
cells (Figures 4E and 4F); sphere size was similar (data not
shown). We also depleted Stat3 from Nf1fl/fl;DhhCre neurofi-
broma SCP spheres with short hairpin RNA (shRNA). Sphere
numbers were significantly reduced 4 days after shStat3 infec-Cetion, versus non-target controls (Figure S4A); we confirmed
decreased Stat3 by western blot (Figure S4B). Thus, Stat3
increases Nf1 mutant SCP self-renewal. In many cancers,
self-renewing stem and/or progenitor-like cells contribute to tu-
morigenesis. Neurofibroma-like lesions were detected in seven
out of eight nu/nu mice that were subcutaneously transplanted
with Nf1fl/fl;DhhCre mice derived sphere cells (Figures 4G and
4H), while no lesion was detected in Stat3fl/fl;Nf1fl/fl;DhhCre
derived sphere cells (Figure 4G). H&E staining of tissue sections
showed no features of malignancy (Figure 4I) and anti-S100b+ll Reports 14, 1979–1990, March 1, 2016 ª2016 The Authors 1983
Figure 4. Stat3 Contributes to Neurofibroma Initiation
(A) The JAK2/STAT3 inhibitor FLLL32 inhibits formation of human neurofibroma spheres. DMSO (0) served as control.
(B) Phase contrast images of human neurofibroma spheres treated with FLLL32 for 5 days.
(C) Western blot of P-STAT3-Y705 and STAT3 in human neurofibroma spheres, ±0.3 mM FLLL32.
(D) Low doses of FLLL32 inhibit formation of mouse E12.5 Nf1/ spheres; effects on E12.5 WT spheres are observed only at higher concentrations.
(E) Phase contrast images of primary neurofibroma and/or DRG spheres from Stat3fl/+;Nf1fl/fl;DhhCre mice (left; control) and Stat3fl/fl;Nf1fl/fl;DhhCremice (right).
(F) Primary and secondary neurofibroma and/or DRG sphere number is reduced in the absence of Stat3 (n = 3 per group).
(G) Neurofibroma-like lesions form after subcutaneous injection of Nf1fl/fl;DhhCre neurofibroma sphere cells but not in Stat3fl/fl;Nf1fl/fl;DhhCre mouse derived
neurofibroma sphere cells.
(H) Gross photograph of a lesion (black arrow) under reflected skin in a mouse injected with Nf1fl/fl;DhhCre neurofibroma sphere cells. The ruler shows 1-mm
markings.
(I) H&E stained section of (F); lesion is indicated by white dotted line.
(J) Immunohistochemistry showing S100b+ cells (brown) in tumor. Blue: hematoxylin counterstain.
(K) Toluidine blue staining showing mast cells (black arrows).
(L, M, and N) EM showing that lesions contain SCs, identified by continuous basal lamina and wrapping of small axons (L), blood vessels (M), and mast cells (N).
Scale bars, 50 mm (B and E) and 20 mm (K). Statistics: ordinary one-way ANOVA.cells SCs (Figure 4J) and mast cells (Figure 4K). Electron micro-
scopy (EM) demonstrated that these lesions contained SCs
identified by their continuous basal lamina and wrapping of
small axons (Figure 4L), blood vessels (Figure 4M), and mast
cells (Figure 4N)—all features of neurofibroma. These in vitro
and in vivo genetic results support the conclusion that Nf1/
SCP self-renewal and neurofibroma tumorigenic potential are
regulated by Stat3.1984 Cell Reports 14, 1979–1990, March 1, 2016 ª2016 The AuthorsStat3 Activates b-catenin Signaling
Data in Figures 1 and 2 suggest a Stat3-b-catenin link in neuro-
fibroma SCs. Stabilized b-catenin translocates to the nucleus
and alters target gene transcription (Liu et al., 2002).
Stat3fl/fl;Nf1fl/fl;DhhCre neurofibromas showed significantly
decreased active (nuclear) b-catenin (45%), increased inactive
b-catenin (P-b-catenin, S33, S37, and T41) (591% in cytoplasm,
166% in nucleus), and decreased cyclin D1 expression (>90%) in
Figure 5. b-catenin Signaling Is a Critical Indicator of Stat3 in Neurofibromas
(A) Western blots of nuclear and cytoplasmic proteins from Stat3fl/fl;Nf1fl/fl;DhhCre or Nf1fl/fl;DhhCre mouse neurofibromas and/or DRGs with indicated anti-
bodies.
(B) b-catenin tankyrase inhibitor XAV-939 inhibits formation of Nf1fl/fl;DhhCre mouse neurofibroma spheres. DMSO (0) was the control. Inset: 10 nM XAV-939
inhibited b-catenin expression by 3 days is shown.
(C) Low dose XAV-939 has no effect on the formation of Stat3fl/fl;Nf1fl/fl;DhhCre mouse neurofibroma spheres.
(D) Three shb-catenin shRNA (#88, #89, and #90) each decreasemouse neurofibroma sphere formation, versus non-target lentivirus YFP (NT) or no virus controls.
The inset shows western blot confirming shb-catenin-mediated knockdown of total b-catenin. Anti-b-actin is the loading control. Numbers show the ratio of
b-catenin to b-actin loading control, then to no virus expression level.
(E) Overexpression of b-catenin deltaN90 (DN90) in Stat3fl/fl;Nf1fl/fl;DhhCremouse neurofibroma and/or DRG spheres increased sphere numbers (black) versus
virus (gray, p < 0.001) or no virus controls (white, p < 0.001). Overexpression ofDN90 b-catenin inNf1fl/fl;DhhCremouse neurofibroma and/or DRG spheres did not
significantly increase sphere numbers (black) versus virus (gray, p = 0.15) or no virus (white, p = 0.43). Inset: western blot detects endogenous 92KDa b-catenin
and 60 KDa of overexpression of mutated DN90 catenin in Stat3fl/fl;Nf1fl/fl;DhhCre mouse neurofibroma spheres.
Statistics: ordinary one-way ANOVA. Three independent experiments were performed in (B), (C), and (E).cytoplasm and nucleus versus controls (Figure 5A). In contrast,
P-Erk did not change (Figure 5A). Thus, neurofibroma b-catenin
expression, localization, and target gene expression are regu-
lated by Stat3.
To verify this conclusion in a system amenable for mechanistic
analysis, we isolated SCPs from Nf1fl/fl;DhhCre neurofibromas
and cultured them with or without blocking b-catenin signaling
with the tankyrase inhibitor XAV-939, which stabilizes axin, a
component of the b-catenin destruction complex. XAV-939 in-
hibited mouse neurofibroma sphere formation (IC50, 0.1 mM).
Western blot confirmed a 50% decrease in total b-catenin with
3 days of drug exposure (10 nM) (Figure 5B). Supporting the hy-
pothesis that Stat3 is critical for b-catenin expression, remark-Ceably, Stat3fl/fl;Nf1fl/fl;DhhCre mouse neurofibroma spheres were
insensitive to 1003 higher concentrations of XAV-939 (Fig-
ure 5C). Depleting b-catenin with shRNA inNf1fl/fl;DhhCre neuro-
fibroma SCP-like spheres also significantly reduced sphere
numbers versus controls (Figure 5D); we confirmed decreased
b-catenin by western blot (Figure 5D, inset). Thus, b-catenin
stabilization requires Stat3 in Nf1/ neurofibroma derived
SCP-like cells.
If b-catenin is critical in Stat3-driven neurofibromagenesis,
then Stat3fl/fl;Nf1fl/fl;DhhCre spheres, which do not form
tumors, should be rescued by b-catenin. To test this, we in-
fected spheres with a stable, active b-catenin mutant (DN90
b-catenin) or virus control. Remarkably, overexpression ofll Reports 14, 1979–1990, March 1, 2016 ª2016 The Authors 1985
DN90 b-catenin significantly increased the number of
Stat3fl/fl;Nf1fl/fl;DhhCre, but not Nf1fl/fl;DhhCre, neurofibroma
spheres (Figure 5E). Importantly, seven out of nine mice in-
jected with DN90 b-catenin infected Stat3fl/fl;Nf1fl/fl;DhhCre
spheres developed neurofibroma-like lesions, while no lesions
were detected in vector controls. Thus, b-catenin is a major
effector of Stat3 signaling in SCP and is necessary for
neurofibromagenesis.
Stat3 Alters Gsk3b Inhibitory Phosphorylation
We wondered how Stat3 activates b-catenin in neurofibromas.
Gsk3b was a frequent CIS identified in our insertional mutagen-
esis screen, which predicted reduced GSK3b (Figure 1).
GSK3b(Ser9) phosphorylation inhibits GSK3b activity, allowing
b-catenin stabilization or activation (Wu and Pan, 2010). STAT3
can negatively regulate GSK3b transcription (Moh et al., 2008).
Gsk3b mRNA expression increased in Stat3fl/fl;Nf1fl/fl;DhhCre
versus Nf1fl/fl;DhhCre neurofibromas (Figure S5A), supporting
the idea that Stat3 transcriptionally represses Gsk3b in neurofi-
bromas. Chromatin immunoprecipitation (ChIP) using anti-
Stat3 detected Stat3 bound to the Stat3 binding motif in the
Gsk3b 50 UTR in neurofibroma DNA (Figures S5B and S5C).
Furthermore, in the absence of Stat3 total Gsk3b increased
in neurofibromas (Figure S5D). Thus, in neurofibromas Stat3
represses Gsk3b transcription, correlating with a reduction in
Gsk3b protein. However, targeting Gsk3b with shRNA only
slightly rescued sphere formation in Stat3fl/fl;Nf1fl/fl;DhhCre
SCP spheres (Figure S5E), suggesting the existence of additional
pathways.
Stat3 Transcriptionally Represses Arid1b Expression
Arid1b was another frequent CIS identified by insertional muta-
genesis (Figure 1A). Transposon insertions into the Arid1b locus
predicted disrupted C termini or truncated N termini, e.g., inac-
tivating insertions, and anti-Arid1b immunofluorescence was
strong in WT SCs but reduced in neurofibroma SCs (Fig-
ure S6A). qRT-PCR confirmed negative regulation of Arid1b
mRNA expression in neurofibromas by Stat3 (e.g., Arid1b
mRNA is low in neurofibromas and increases in the absence
of Stat3; Figure 6A). Similar results were observed in fluo-
rescence-activated cell sorting (FACS)-sorted EGFP+ neu-
rofibroma SCs versus WT SCs (Figure S6B). We identified a
putative Stat3 binding site 7 kb downstream of the mouse
Arid1b transcriptional start site (Figures 6B and S7). When
Nf1fl/fl;DhhCre neurofibroma DNA was subjected to ChIP using
anti-Stat3, we detected Stat3 bound to Arid1b at this site by
PCR (Figure 6C).
Arid1b expression was low in Nf1fl/fl;DhhCre and high in
Stat3fl/fl;Nf1fl/fl;DhhCre tumor-derived neurofibroma spheres
(data not shown). We exposed Stat3fl/fl;Nf1fl/fl;DhhCre neurofi-
broma spheres to shArid1b. Decreasing Arid1b expression
significantly increased sphere numbers (Figure 6D), correlating
with elevated levels of activated b-catenin protein (Figure 6E)
and mRNA expression (Figure 6F), and elevated levels of the
b-catenin target genes Axin2, Ccnd1, and Myc (Figure 6F).
shGsk3b increased b-catenin and its target gene mRNA
expression in Stat3fl/fl;Nf1fl/fl;DhhCre spheres (Figure 6G) but
did not rescue numbers of Stat3fl/fl;Nf1fl/fl;DhhCre spheres (Fig-1986 Cell Reports 14, 1979–1990, March 1, 2016 ª2016 The Authorsures 7Band S5E). Knockdown of Gsk3b and Arid1b simulta-
neously with shRNA showed similar effects to shArid1b alone
(Figure 7A).
To test whether tumor formation is affected by reduction in
Arid1b, Gsk3b, or both, we transplanted sphere cells into nude
mice. Stat3fl/fl;Nf1fl/fl;DhhCre spheres rarely formed tumors. Tu-
mors formed in Stat3fl/fl;Nf1fl/fl;DhhCre sphere cells infected
with shGsk3b, shArid1b, or shArid1b + shGsk3b by 8 weeks after
transplantation (p = 0.0157; Figure 7B). There were no significant
differences between the three experimental groups (p = 0.3669),
suggesting both Gsk3b and Arid1b are involved in Stat3-medi-
ated neurofibromagenesis.
ARID1B acts in SWI/SNF complexes containing BRG1, the
central catalytic subunit of numerous chromatin-modifying enzy-
matic complexes (Trotter and Archer, 2008). BRG1 can be
required for Stat3 recruitment to target genes (Ni and Bremner,
2007). To test whether Arid1b requires Brg1 to affect sphere
numbers, we knocked down Brg1 and/or Arid1b in
Stat3fl/fl;Nf1fl/fl;DhhCre spheres with shRNA. The low numbers
characteristic of Stat3fl/fl;Nf1fl/fl;DhhCre spheres were rescued
by shArid1b, but not shBrg1. The combination of shArid1b
together with shBrg1 prevented the shArid1b effect, indicating
that the effect requires Brg1 and most likely chromatin remodel-
ing (Figure 7C).
Stat3 binds the Arid1b promoter fragment, repressing Arib1b
expression. Arid1b’s known function is in chromatin remodel-
ing, and we wondered if the Arid1b gene itself might be subject
to Stat3-dependent histone modification. We performed ChIP
with antibodies recognizing the histone modifications
H3K4Me3, H3K9Me2, and H3K9Ac in vehicle or Stat3 inhibitor
(FLLL32) treated primary mouse neurofibroma SCs at the
Arid1b promoter. We detected a significant enhancement in
the H3K4Me3 marks at the Arid1b promoter in three indepen-
dent experiments (p < 0.05). In contrast, H3K9Me2 or
H3K9Ac did not significantly change at this site after FLLL32
exposure (Figure 7D). Taken together, in the setting of Nf1
loss, Stat3 transcriptionally represses the SWI/SNF gene
Arid1b through histone H3K4Me3 modification and this repres-
sion is BRG1 dependent (Figure 7E). This results in an increase
in b-catenin.
DISCUSSION
By performing an unbiased insertional mutagenesis screen and
using mouse genetics and SCP culture, we identified an Nf1/
P-Stat3/Arid1b/b-catenin pathway in SCP that is critical for
neurofibroma initiation. P-Stat3 is a major neurofibroma onco-
gene as targeted genetic deletion of Stat3 in nerve SCs and
SCPs dramatically delays neurofibroma formation and tumors,
once formed, grow very slowly (Figures 2A–2C). Stat3 provides
a first example of a genetic loss of function affecting neurofi-
broma initiation and growth in vivo. Loss of Stat3 decreased
numbers of neurofibroma SCP-like cells, neurofibroma SCP
self-renewal, and neurofibroma formation by SCP after trans-
plantation, functions defining cancer stem- and/or progenitor-
like cells in tumor initiation (Figure 4). Importantly, b-catenin
expression rescued all phenotypes driven by Stat3 loss of func-
tion in Nf1mutant SCPs (Figure 5E). Supporting the relevance of
Figure 6. Stat3 Transcriptionally Represses Arid1b Expression, Activating b-catenin
(A) qRT-PCR shows high Arid1b mRNA in Stat3fl/fl;Nf1fl/fl;DhhCre mouse sciatic nerve (white, n = 6) versus WT (n = 6) and Nf1fl/fl;DhhCre nerve (n = 6).
(B) Schematic, exon 1 mouse Arid1b gene. A putative Stat3 binding motif is between Exon 1 and Exon 2; the binding motif sequence is shown in bold.
(C) Stat3 on the Arid1b promoter. PCR amplified a 139-bp Arid1b DNA fragment after ChIP with anti-Stat3. IgG was the negative control.
(D) Two Arid1b shRNA increase the number of Stat3fl/fl;Nf1fl/fl;DhhCre mouse neurofibroma spheres.
(E) Western blot shows knockdown of Arid1b and increased b-catenin in Stat3fl/fl;Nf1fl/fl;DhhCremouse neurofibroma spheres 4 days after shArid1b infection in
two different shRNA clones.
(F and G) b-catenin target gene expression increases after shArid1b (F) or shGsk3b (G) infection of Stat3fl/fl;Nf1fl/fl;DhhCre neurofibroma spheres.
Mean ± SEM is shown for three independent experiments and two clones of shRNA in (D), (F), and (G). A representative experiment (of three) is shown in (C).
Statistics: ordinary one-way ANOVA.our findings to human neurofibromas, primary patient-derived
neurofibroma SCP-like cell sphere formation, a surrogate of tu-
mor initiation, was dramatically reduced by Jak2/Stat3 inhibition
(Figure 4A), and P-Y705-STAT3 and b-catenin expression were
highly correlated in human plexiform neurofibromas (Figure 2).
We confirmed that Stat3 and b-catenin are detectable in hu-
man plexiform neurofibromas and demonstrated that Stat3 and
b-catenin are critical for neurofibroma formation in transplanta-
tion (Figure 5G). The Sleeping Beauty system and pathway anal-
ysis defined mutations predicting loss of Gsk3b and Arid1b,
identifying the WNT and STAT pathways as players that might
cooperate with loss of Nf1 in neurofibromagenesis (Figure 1).
GSK3b and b-catenin signaling were previously implicated in
MPNST, sarcomas that are malignant derivatives of neurofi-
bromas (Mo et al., 2013; Rahrmann et al., 2013; Watson et al.,
2013). Other CIS genes (WAPAL, SP3, BTBD9, and IGFR1) are
upregulated in neurofibroma cells, suggesting roles as proto-on-
cogenes early in tumor progression. Downregulated CIS genesCe(TMCC3, SLC35F1, and SORCS) may have tumor suppressor
functions.
Stat3 is present on the Gsk3b promoter in neurofibromas (Fig-
ure S5), consistent with Stat3 repressing GSK3b transcription in
hepatocytes (Moh et al., 2008). In SCP, decreasing Gsk3b also
increased b-catenin target gene expression, and tumor forma-
tion, but did not rescue SCP sphere formation. Given that
shGsk3b or shArid1b enable tumor formation and b-catenin
expression, but only shArid1b rescues neurofibroma sphere
numbers, these genes likely use different mechanisms to repress
b-catenin function; loss of either is sufficient to drive neurofi-
broma formation in the absence of Stat3, suggesting that inter-
ference with b-catenin signaling by one of several mechanisms
will interfere with tumor formation.
We identifyArid1b as a critical link between P-Stat3 and b-cat-
enin. ARID1B is a tumor suppressor, mutated by deletion, in
neuroblastoma (Sausen et al., 2013). The ARID1B promoter
can be hyper-methylated, resulting in decreased ARID1Bll Reports 14, 1979–1990, March 1, 2016 ª2016 The Authors 1987
Figure 7. Arid1b and Gsk3b Contribute to
Stat3 Mediated Neurofibromagenesis
(A) In vitro, shGsk3b does not fully rescue
Stat3fl/fl;Nf1fl/fl;DhhCre sphere numbers. Simulta-
neous knockdown of Gsk3b and Arid1b shows
similar effects to shArid1b alone.
(B) Neurofibroma-like tumors form in Stat3fl/fl;
Nf1fl/fl;DhhCre sphere cells infected with shArid1b,
shGsk3b, or both and transplanted into nu/nu
mice.
(C) Brg1 is necessary for Stat3fl/fl;Nf1fl/fl;DhhCre
sphere formation in cells treated with shArid1b.
(D) ChIP shows enhancement of the H3K4Me3
mark at the Arid1b promoter.
(E) Schematic shows a model of neurofibroma
initiation; loss of Nf1 in SCP causes activation of
P-Stat3. P-Stat3 transcriptionally represses
Arid1b and Gsk3b, increasing b-catenin activity.
Mean ± SEM is shown for three independent ex-
periments in (A), (C), and (D). Two different shRNA
clones (#1 and #2) were used in (A) and (C). For
combination, we used shArid1b #1+shGsk3b #1
(white bar) or shArid1b #2+shGsk3b #2 (gray bar)
in (A). We used shArid1b #1+shBrg1 #1 (white bar)
and shArid1b #2+shBrg1 #2 (gray bar) in (C).
Statistics: ordinary one-way ANOVA.expression, as in pancreatic cancer cells (Khursheed et al.,
2013). Arid1b also functions as a tumor suppressor in the context
of Nf1 loss, with low expression in neurofibromas resulting in
increased b-catenin, Wnt/b-catenin target gene expression,
and tumorigenesis (Figure 6). There was variation in the extent
of Wnt/b-catenin target gene expression among samples with
shRNA exposure, which is likely due to our use of primary cells.
The differentiation state of individual cells in spheres and/or
different levels of shRNA expression after lentiviral infection
may account for this variation. Although our study was nearing
completion, Vasileiou et al. (2015) showed that, as in our study,
reducing ARID1B increases Wnt/b-catenin target gene expres-
sion. They also overexpressed ARID1B by transient transfection
and inhibited Wnt/b-catenin activity in cell lines. We were unable
to overexpress ARID1B, as the ARID1B cDNA is too large for the
lentiviral infection required in our primary cells. Nevertheless,
together the two studies strongly support critical roles for
ARID1B in regulation of Wnt/b-catenin activity.
We detected increased H3K4Me3 at the Arid1b promoter re-
gion after Stat3 inhibition. Given that the Stat3 binding site is in
intron 1 of the Arid1b gene, it is likely that Stat3 binds to this in-
tronic region and regulates Arid1b by antisense transcription, a
mechanism by which mammalian genes regulate sense tran-
scription (Faghihi and Wahlestedt, 2009; Magistri et al., 2012).
Genome-wide mapping of chromatin modification will be neces-
sary to further clarify this mechanism.1988 Cell Reports 14, 1979–1990, March 1, 2016 ª2016 The AuthorsIn summary, loss of Nf1 activates Stat3
SCPs, enabling tumor initiation by repres-
sing the SWI/SNF gene Arid1b through
histones H3K4Me3 and H3K27Me3
modification, thereby activating b-cate-
nin. Knockdown of Arid1b in Stat3fl/f;Nf1fl/fl;DhhCre SCPs by shRNA is sufficient to recue neurofi-
broma formation in in vivo transplantation. Mouse and human
NF1 mutant cells are significantly more sensitive than their WT
counterparts to treatment with a JAK2/STAT3 inhibitor (Figures
4A and 4D), suggesting that a therapeutic window will exist for
neurofibroma therapy using JAK/STAT pathway inhibitors now
in clinical trials (Lesina et al., 2011). Given that b-catenin targeted
therapeutics are not yet proven, blocking b-catenin via STAT or
targeting SWI/SNF complexes may be feasible strategies.
EXPERIMENTAL PROCEDURES
Animals
Mice were housed in temperature- and humidity-controlled facilities on 12-hr
dark-light cycles with free access to food and water. The animal care and use
committees of Cincinnati Children’s Hospital Medical Center or University of
Minnesota approved all animal procedures. See the Supplemental Experi-
mental Procedures for additional details.
Pyrosequencing and Genemania Analysis
T2/Onc integration sites from 49 neurofibromas were cloned and sequenced
using bar-coded primers and linker-mediated PCR, followed by pyrosequenc-
ing. Amplicon sequencing using the GS20 Flex pyrosequencing machine
(Roche) was performed according to the manufacturer’s protocol. Primers
used a unique 10-bp barcode-recognition sequence for each tumor sample.
After removal of redundant and other non-specific noise as described (Keng
et al., 2009), we obtained 6,353 non-redundant insertions. Next, we identified
CISs with more Sleeping Beauty mutagenic transposon insertions than
predicted based onMonte Carlo criteria for statistical significance.We defined
CISs as regions in the genome with six insertions located within 185 kb of each
other, five insertions within 95 kb, four insertions within 35 kb, or three inser-
tions within 5 kb. We used the Genemania algorithm to generate gene-gene
association networks (genetic interaction, physical interaction, and pathways),
after inputting these CIS. This generated networks, each of whichwe extended
using the top 20 related genes precomputed in the program. These are defined
as neighboring genes. We similarly colored genes significantly enriched in a
given ‘‘biological process’’ within a Gene Ontology (GO) category, after
applying a significance cutoff of FDR < 0.05).
Embryonic and Neurofibroma Sphere Formation and SC Culture
Embryonic mouse spheres dissociated from E12.5 DRG with 0.25% Trypsin
20 min. at 37C (Mediatech) produced single-cell suspensions with narrow-
bore pipettes and a 70-mm strainer (BD-Falcon). For mouse or human neuro-
fibroma spheres, we chopped tissue into 1–3 mm3 pieces, which were plated
in 20ml L-15 (Mediatech) plus 0.5 mg/ml collagenase type 1 (Worthington) and
2.5mg/ml dispase protease type II (Cambrex) at 37C for 4–6 hr.We plated try-
pan blue negative cells (STEMCELL) at 13 104 cells in 1 ml per well in 24-well
low-binding plates in medium containing DMEM:F-12 (3:1) + 20 ng/ml rhEGF
(R&D Systems), 20 ng/ml rh bFGF (R&D Systems), 1% B-27 (Invitrogen), and
2 mg/ml heparin (Sigma-Aldrich). We maintained cultures at 37C and 5%
CO2 and counted floating spheres after 4–7 days. To passage, we centrifuged
sphere cultures, which were dissociated and plated at 13 104 cells/ml in fresh
sphere medium as described (Williams et al., 2008). For each experiment, we
show a representative of three independent experiments.
Immunohistochemistry
Tissue was embedded in paraffin, and 6-mm sections were cut and stained
with either H&E or toluidine blue or were incubated overnight at 4C with the
following antibodies: anti-S100b (Dako), Ki67 (Novacastra Leica Microsys-
tems), anti-P-Stat3 (Y705), anti-cleaved caspase 3, or b-catenin (Cell Signaling
Technology). Visualization methods were as described (Williams et al., 2008).
Western Blots
Western blots were performed using antibodies recognizing P-Jak2, Jak2,
P-Stat3, Stat3, P-b-catenin, b-catenin, P-GSK3b, GSK3b, and b-actin (Cell
Signaling Technology). At least three different tumor and/or cell lysates were
analyzed per antigen.
Tumorigenesis Assay in Nude Mice
We injected 53 105mouse sphere cells/injection subcutaneously into athymic
female nudemice (Harlan). After 2months we dissected tumors and fixed them
in 4% paraformaldehyde overnight, which were then embedded in paraffin for
histology.
Measurement of Tumor Number and Tumor Size
We perfused each mouse intracardially with 4% paraformaldehyde (w/v) in
PBS, which were then incubated overnight in 300 ml 4% paraformaldehyde,
incubated overnight, again, in 50 ml decalcification solution (Cal-Rite, Richard
Allan Scientific), and then transferred to PBS. Using a Leica dissecting micro-
scope, we dissected the spinal cord with attached DRG and nerve roots, and
counted tumors. A tumor was defined as a mass surrounding the DRG and/or
nerve roots, with a diameter greater than 1 mm, measured perpendicular to
DRG and/or nerve roots.
Tumor Volumetric Measurement
MRI imaging and volumetric measurement of neurofibromas and statistical an-
alyses using mixed effects modeling were as described (Wu et al., 2012).
Lentiviral Infection
We infected secondary Nf1fl/fl;DhhCre neurofibroma spheres or
Stat3fl/fl;Nf1fl/fl;DhhCre DRG/neurofibroma spheres with shRNA and non-
target control (Sigma-Aldrich), b-catenin overexpression lentivirus DN90
(Addgene), or same backbone control (Sigma-Aldrich). We incubated lentiviral
particles with neurofibroma spheres for 3–5 days and counted sphere
numbers. For in vivo xenografts, Stat3fl/fl;Nf1fl/fl;DhhCre DRG/neurofibromaCespheres were infected with lentivirus in the presence of polybrene (8mg/ml;
Sigma-Aldrich) for 16–20 hr, followed by selection in G418 (500 mg/ml;
Sigma-Aldrich). Spheres were collected and dissociated for xenograft
injection.
Statistics
Kaplan-Meier analysis used a Gehan-Breslow-Wilcox log-rank test. Neurofi-
broma growth was modeled by mixed effects model analysis. p values were
generated with a random effects model analysis of log transformed tumor
volume data using the SASmixed procedure (Jessen et al., 2013). We used un-
paired two-tailed Student’s t tests to analyze significance of cell proliferation
and cell death quantification in tissue sections when two samples were
compared. Other experiments used ordinary one-way ANOVA, reported as
mean ± SEM; p < 0.05 was considered significant.SUPPLEMENTAL INFORMATION
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